ALLMedicine™ Bladder Cancer Center

Mar 3rd, 2021 - Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the killing...

Mar 3rd, 2021 - The feasibility and safety of robot-assisted radical cystectomy (RARC) may be undermined by unfavorable preoperative surgical characteristics such as previous prostate surgery (PPS). To compare perioperative outcomes for patients undergoing RARC w...

Mar 3rd, 2021 - Transurethral resection of bladder tumour (TURBT) is central to the diagnosis of muscle-invasive bladder cancer (MIBC). With the oncological safety of TURBT unknown, staging inaccuracies commonplace, and correct treatment of MIBC potentially delay...

Mar 2nd, 2021 - Non-bacterial thrombotic endocarditis (NBTE) is characterized by the deposition of fibrin and platelet thrombi on previously undamaged heart valves in the absence of bloodstream infection. It is associated with chronic disease states and can prese...

Mar 2nd, 2021 - Bladder cancer (BC), a common urologic cancer, is the fifth most frequently diagnosed tumor worldwide. hsa‑miR‑34a displays antitumor activity in several types of cancer. However, the functional mechanisms underlying hsa‑miR‑34a in BC remains larg...

May 27th, 2020 - Is maintenance therapy with an immune checkpoint inhibitor a good idea for patients with advanced bladder cancer who do not progress after initial chemotherapy?

May 27th, 2020 - Maintenance therapy with a PD-L1 immune checkpoint inhibitor improved overall survival (OS) for patients with advanced bladder cancer and stable disease following first-line chemotherapy, an interim analysis of a phase III trial found.

Feb 24th, 2020 - During the 2019 International Society of Urological Pathology Consultation Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder Cancer presented the current status and made recommendations on the diagnostic use of m...

Jan 28th, 2020 - Despite an increased use of neoadjuvant and adjuvant chemotherapy, the long-term survival rates after radical cystectomy or trimodal therapy (TMT) for muscle-invasive bladder cancer (MIBC) remain basically unchanged for decades. Detection and effe...

Jan 7th, 2020 - The Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)...

Mar 3rd, 2021 - Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the killing...

Mar 3rd, 2021 - The feasibility and safety of robot-assisted radical cystectomy (RARC) may be undermined by unfavorable preoperative surgical characteristics such as previous prostate surgery (PPS). To compare perioperative outcomes for patients undergoing RARC w...

Mar 3rd, 2021 - Transurethral resection of bladder tumour (TURBT) is central to the diagnosis of muscle-invasive bladder cancer (MIBC). With the oncological safety of TURBT unknown, staging inaccuracies commonplace, and correct treatment of MIBC potentially delay...

Mar 2nd, 2021 - Non-bacterial thrombotic endocarditis (NBTE) is characterized by the deposition of fibrin and platelet thrombi on previously undamaged heart valves in the absence of bloodstream infection. It is associated with chronic disease states and can prese...

Mar 2nd, 2021 - Bladder cancer (BC), a common urologic cancer, is the fifth most frequently diagnosed tumor worldwide. hsa‑miR‑34a displays antitumor activity in several types of cancer. However, the functional mechanisms underlying hsa‑miR‑34a in BC remains larg...

Feb 22nd, 2021 - After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be withdrawn in the United States for the immunotherapy durvalumab (Imfinzi), AstraZeneca announced. The withdrawal does n...

Jan 31st, 2021 - The use of low-dose aspirin among older people shows no effect in reducing the incidence of certain cancer types. However, the treatment — particularly with frequency of at least three times a week — is associated with reductions in mortality in b...

Jan 26th, 2021 - My patient, a woman with metastatic bladder cancer who was about to move to a different part of the country, was perplexed: "Can't you just give me my records on a flash drive?" Unfortunately it wasn't that easy. Forms needed to be routed through ...

Dec 28th, 2020 - Bladder cancer, a common urologic cancer, has the highest recurrence rate of any cancer. Globally, approximately 550,000 new cases of bladder cancer are diagnosed and nearly 200,000 deaths from bladder cancer occur each year. Whereas non–muscle-in...

Nov 9th, 2020 - Public Health England (PHE) has published new statistics which show improved survival in most cancers. The data cover a pre-pandemic period so the impact of recent delays in diagnosis and treatment won't be known for some time. The new figures sho...